Released: 11/16/2009
Expires: 11/16/2010
Statement of Need
The purpose of this activiy is to enhance knowledge concerning the treatment of patients with non-Hodgkin lymphomas and multiple myeloma.

Target Audience
This activity was developed for physicians, nurses, and pharmacists.

Learning Objectives
At the completion of this activity participants should be able to:

• List therapeutic options (including those using novel agents) for patients with newly diagnosed and relapsed/refractory MM
• Describe current strategies (including those using novel agents) for the treatment of newly diagnosed and relapsed/refractory NHL
• Describe how emerging clinical trial data can be applied to current clinical practice

Agenda - 1.25 hours
• Articles/Commentaries: 60 minutes
• Evaluation/Post-Test: 15 minutes

Physician Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.25 contact hours.

Registered Pharmacy Designation
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal program number for this activity is 0468-9999-09-048-H01-P.

Instructions for Credit
To receive credit, participants must first take the pretest for this activity. After reading this CE activity in its entirety, participants must complete the posttest and evaluation. The pretest, posttest, and evaluation can be completed online at www.mlicme.org/p09012.html. Upon completion of the evaluation and scoring a 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the certificate for your records.

For questions regarding the accreditation of this activity, please contact Medical Learning Institute at (609) 333-1693 or cgusack@mlicme.org.

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity will disclose the existence of any financial interest and/or relationship(s) theymight havewith themanufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager	Company	Reported Financial Relationship
Amanda Glazar, PhD	Global	Nothing to disclose
Jackie Dawson, MSN	Global	Nothing to disclose
Kathryn Gada, MSN	MLI	Nothing to disclose
Judy Silman-Greenspan, RPh, MPharm Sci	MLI	Nothing to disclose
Karen Cooksey	COEXM	Nothing to disclose
Susan Berry	COEXM	Nothing to disclose

Faculty Disclosures
Kenneth Anderson, MD is on the advisory board for Celgene, Gentium, Millennium, and Novartis, has received grant/research support from Celgene, Millennium, and Novartis, has received honoraria from Celgene, Millennium, and Novartis, and is on the speaker's bureau for Celgene and Millennium.

James O. Armitage, MD is a consultant for Allos, Eisai, Seattle Genetics, and Ziopharm.

Paul Richardson, MD, is on the advisory boards for Bristol-Myers Squibb, Celgene, Johnson & Johnson, and Millennium and has received research support from Millennium.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.